Abstract:Su Yuan, 1, 2 Biao Zuo, 2, 3 Si-Cong Zhou, 1, 2 Meng Wang, 2, 3 Kai-Yue Tan, 2, 3 Zhi-Wei Chen, 2, 3 Wen-Fu Cao 1– 3 1 Department of Combination of Chinese and Western Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China; 2 Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing, People's Republic of China; 3 College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, People's Republic of China Correspondence: Wen-Fu Cao, The First Affiliated Hospital of Chongqing Medical University, No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, 400016, People's Republic of China, Email Purpose: Our study aims to reveal the pharmacological mechanism of Astragaloside IV in the treatment of pulmonary fibrosis(PF) through network pharmacology and experimental validation. Methods: We first determined the in vivo anti-pulmonary fibrosis effect of Astragaloside IV by HE, MASSON staining, and lung coefficients, then used network pharmacology to predict the signaling pathways and molecularly docked key pathway proteins, and finally validated the results by in vivo and in vitro experiments. Results: In in vivo experiments, we found that Astragaloside IV improved body weight (P < 0.05), increased lung coefficients (P < 0.05), and reduced lung inflammation and collagen deposition in mice with pulmonary fibrosis. The network pharmacology results showed that Astragaloside IV had 104 cross-targets with idiopathic pulmonary fibrosis, and the results of KEGG enrichment analysis indicated that cellular senescence could be an important pathway for Astragaloside IV in the treatment of pulmonary fibrosis. Astragaloside IV also bound well to senescence-associated proteins, according to molecular docking results. The results of both in vivo and in vitro experiments showed that Astragaloside IV significantly inhibited senescence protein markers such as P53, P21, and P16 and delayed cellular senescence (P < 0.05). In in vivo experiments, we also found that Astragaloside IV reduced the production of SASPs (P < 0.05), and in in vitro experiments, Astragaloside IV also reduced the production of ROS. In addition, by detecting epithelial-mesenchymal transition(EMT)-related marker protein expression, we also found that Astragaloside IV significantly inhibited the development of EMT in both in vivo and in vitro experiments (P < 0.05). Conclusion: Our research found that Astragaloside IV could alleviate bleomycin-induced PF by preventing cellular senescence and EMT. Keywords: astragaloside IV, pulmonary fibrosis, network pharmacology, cellular senescence, epithelial-mesenchymal transition Idiopathic pulmonary fibrosis (IPF) affects the lung parenchyma and is characterized by a decline in lung functions, abnormal deposition of extracellular matrix, and interstitial fibrosis that worsens with time. 1,2 The incidence of PF has been rising year after year in recent years; 3 however, IPF's onset and progression have complex mechanisms that are still unknown. 4–6 In addition to the recognized risk factors for IPF, such as smoke, environmental elements, comorbidities, and viral infections, various other processes are associated with the disease. Aging, epithelial-mesenchymal transition (EMT), endothelial-mesenchymal transfer, and epithelial cell migration are important factors in IPF-related tissue remodeling. 7 Pulmonary fibrosis (PF) is difficult to diagnose and incurable in the early stages and the prognosis is poor, with a 5-year survival <30% and an average survival time following diagnosis of 2–3 years. 8,9 Moreover, the incidence of PF is gradually increasing worldwide. 10 Nevertheless, there is a lack of effective drug therapy for IPF. Therefore, we need to urgently explore the exact molecular mechanisms of IPF progression for developing new therapeutic approaches. Astragaloside-IV (AS-IV) is a cycloartane triterpenoid and a key active compound of Astragalus . It exerts numerous medicinal uses, such as anti-inflammatory, antifibrotic, antiasthmatic, antidiabetic, and immunoregulatory through various signaling channels. 11 Current research and clinical experience indicate that AS-IV has a wide range of potential applications in several diseases. For instance, it slows the advancement of renal fibrosis by inhibiting the TGF-β/Smad signaling pathway. 12 In addition, AS-IV significantly delays the progression of liver fibrosis through the PAR2 signaling pathway -Abstract Truncated-

Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway

Astragaloside Iv Improves Bleomycin-Induced Pulmonary Fibrosis in Rats by Attenuating Extracellular Matrix Deposition

Astragaloside Iv Stimulates Angiogenesis And Increases Hypoxia-Inducible Factor-1 Alpha Accumulation Via Phosphatidylinositol 3-Kinase/Akt Pathway

Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response

Astragaloside IV attenuates hypoxia‑induced pulmonary vascular remodeling via the Notch signaling pathway

Astragaloside IV attenuates inflammatory response mediated by NLRP‐3/calpain‐1 is involved in the development of pulmonary hypertension

Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway

Integrating Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanism of Astragaloside IV in Treating Bleomycin-Induced Pulmonary Fibrosis

Astragaloside IV protects against lung injury and pulmonary fibrosis in COPD by targeting GTP-GDP domain of RAS and downregulating the RAS/RAF/FoxO signaling pathway

Astragaloside IV promotes the pyroptosis of airway smooth muscle cells in childhood asthma by suppressing HMGB1/RAGE axis to inactivate NF-κb pathway

Astragaloside IV inhibits idiopathic pulmonary fibrosis through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway

Astragaloside IV inhibits angiotensin II-induced atrial fibrosis and atrial fibrillation by SIRT1/PGC-1α/FNDC5 pathway

Astragaloside IV inhibits proliferation and promotes apoptosis in rat vascular smooth muscle cells under high glucose concentration in vitro.

Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the Mtorc1 Signaling Pathway

Astragaloside IV Inhibits Cardiac Fibrosis Via Mir-135A-trpm7-tgf-β/smads Pathway.

Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway

Astragaloside IV Inhibits Lung Injury and Fibrosis Induced by PM2.5 by Targeting RUNX1 Through miR-362-3p

Pharmacological Effects of Astragaloside IV: A Review

Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects

[Astragaloside II Inhibits the Proliferation of Rat Pulmonary Artery Smooth Muscle Cells Induced by Hypoxia Via Blocking NOX/ROS/AKT/mTOR Signaling Pathway].

Astragaloside Iv Inhibits Pma-Induced Epcr Shedding Through Mapks and Pkc Pathway